Targeted approaches for the management of metastatic prostate cancer.
Huggins and Hodges described the first systemic targeted therapy for prostate cancer in 1941 with their report on the effects of androgen ablation in men with metastatic disease. Since that time, researchers have identified multiple additional "targets" that may be important in prostate cancer tumorigenesis. These areas include continued emphasis on the androgen receptor in the androgen-independent state, parallel growth pathways such as AKT and HER2 that may act in conjunction or independently of the androgen receptor, the supporting environment that allows for the development of metastatic disease, and standard cytotoxic targets, such as the microtubule. This review is intended to highlight these potential targets and several of the agents that are under development in the treatment of prostate cancer.
Beekman
Kathleen W
KW
Genitourinary Oncology Service, Department of Medicine, Division of Hematology-Oncology, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, C-409/0843 MIB, Ann Arbor, MI, 48109-0843, USA. katew@umich.edu
Hussain
Maha
M
D000971:Antineoplastic Combined Chemotherapy Protocols; D016503:Drug Delivery Systems; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000639:trends; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics; D011944:Receptors, Androgen / Q000187:drug effects
D016228:Endothelial Growth Factors; D011944:Receptors, Androgen